New approaches to the systemic treatment of melanoma

Cancer Treatment Reviews

Volumn 25, Issue 5, 1999, Pages 259-270

  Chowdhury, S ^a   Vaughan, M M ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biochemotherapy; Chemotherapy; Interferon; Melanoma; Vaccines

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETULIC ACID; BLEOMYCIN; CANCER VACCINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LETHARGY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; MYALGIA; NAUSEA; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; VASCULAR DISEASE; VOMITING;

EID: 0032756309     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0138     Document Type: Article

References (71)

1. DeVita, V. J.Hellman, S.Rosenberg, S. A. Cancer Principles and Practises of Oncology, 1947, 1979.
2. Barth A., Wanek L. A., Morton D. L. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg. 181:1995;193-201.
3. Tomsu K., Van Eschen K. B., Lee M. A. meta-analysis of median survival of patients with stage IV melanoma. Proc Am Soc Clin Onc. 16:1997;1784.
4. Comis, R. L. DTIC in malignant melanoma: a perspective. Cancer Treat Rep, 60, 165, 176.
5. Lee S. M., Betticher D. C., Thatcher N. Melanoma: chemotherapy. Br Med Bull. 51:1995;609-630.
6. Kleeberg U. R., Engel E., Israels P. Palliative therapyof melanoma patients with fotemustine. Inverse relationship between tumour load and effectiveness. A multi-centre phase II trial of the EORTC-melanoma cooperative group (MCG). Melanoma Res. 5:1995;195-200.
7. D'Incali M., Citti L., Taverna P. Importance of DNA repair enzyme O6 alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev. 15:1988;279-292.
8. Avril M. F., Gerard B. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma Res. 2:1992;147-151.
9. Lee S. M., Margison G. P., Woodcock A. A. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer. 67:1993;1356-1360.
10. Bleehen N. M., Newlands E. S., Lee S. M. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Onc. 13:1995;910-913.
11. Lee S. M., Thatcher N., Crowther D. Inactivation of O6 alkylguanine DNA alkyltransferase in human peripheral blood mononuclear cells by temozolamide. Br J Cancer. 69:1994;452-456.
12. Middleton M. R., Gore M. E., Tilgen W. A randomised phase III study of temozolamide versus dacarbazine in treatment of patients with advanced, metastatic melanoma. Proc Am Soc Clin Oncol. 18:1999;536a.
13. Pisha E., Chai H., Lee I. S. Discovery of betulinic acid as a selective inhibitor that functions by induction of apoptosis. Nat Med. 1/10:1995;1046-1051.
14. Luikart S. D., Kennealey G. T., kirkwood J. M. Randomised phase III trial of vinblastine, bleomycin and cis-dichlorodiamine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 2:1984;164-168.
15. Buziad A. C., Legha S., Winn R. Cisplatin (C), vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III cancer community oncology program (CCOP trial). Proc Am Soc Clin Oncol. 12:1993;389.
16. Del Prete S. A., Maurer L. H., O'Donnell J. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 68:1984;1403-1405.
17. McClay E. F., McClay M. Systemic chemotherapy for the treatment of metastatic melanoma Semin. Oncol. 23:1996;744-753.
18. Rusthoven J. J., Quirt I. C., Iscoe N. A. Randomized, double blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 14:1996;2033-2090.
19. Johnston S. R., Constenia D. O., Moore J. Randomised phase II trial of BCDT (BCNU, cisplatin, dacarbazine and tamoxifen) with or without interferon alpha and iterleukin-2 in patients with metastatic melanoma. Br J Cancer. 77(8):1998;1280-1286.
20. Sileni V. C., Nortilli R., Medici M. B.C.N.U(B) cisplatin (C) dacarbazine (D) and tamoxifen (T) (BCDT) in metastatic melanoma (MM): results of a randomized phase II study. Proc Am Soc Clin Onc. 16:1997;495a.
21. Middleton M., Lorigan P., Owen J. Dacarbazine, BCNU, cisplatin and tamoxifen (DBCT) versus dacarbazine and interferon (DI) in advanced malanoma, interim results of a randomised phase III study. Proc Am Soc Clin Onc. 17:1998;1958.
22. Cocconi G., Bella M., Calabresi F. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 20 (Aug):1992;516-523.
23. Saxman S. B., Meyers M. L., Chapman P. B. A Phase III multicentre randomised trial of DTIC, cisplatin, BCNU and tamoxifen vs. DTIC alone in patients with metastatic melanoma. Proc Am Soc Clin Onc. 18:1999;2068.
24. Veronesi U., Adamus J., Auebert C. A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Eng J Med. 307:1982;913-916.
25. Fisher R. I., Terry W. D., Hodes R. J. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the NCI randomised trial. Surg Clin North Am. 61:1981;1267-1277.
26. Lejeune F. J., Macher E., Kleeberg U. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC 18761). Eur J Cancer. 24 (suppl2):1988;81-90.
27. Hill G. J., Moss S. E., Golomb F. M. DTIC and combination therapy for melanoma III. Surgical adjuvant study COG protocol 7040. Cancer. 47:1981;2556-2562.
28. Legha S. S. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol. 24 (Suppl 4):1997;24-31.
29. Cascinelli M. Evaluation of the efficacy of adjuvant interferon alpha in melanoma patients with regional lymph node metastases. Proc Am Soc Clin Oncol. 14:1995;410.
30. Creagan E. T., Dalton R. J., Ahmann D. L. Randomised adjuvant surgical clinical trial of recombinant interferon alpha 2a in selected patients with malignant melanoma. J Clin Oncol. 13:1995;2776-2783.
31. Kirkwood J. M., Strawderman M. H., Ernstoff M. S. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial 1684. J Clin Oncol. 14:1996;7-17.
32. Cole B. F., Gelber R. D., Kirkwood J. M. Quality of life adjusted survival analysis of interferon alpha 2b adjuvant treatment of high-risk resected cutaneous melanoma; an ECOG study. J Clin Oncol. 14:1996;2666-2673.
33. Kirkwood J. M., Ibrahim J., Sondak V. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high- and low-dose interferon alpha 2b in high-risk primary or lymph node metastatic melanoma. Proc Am Soc Clin Oncol. 18:1999;537a.
34. Penhamberger H., Soyer P., Steiner A. Adjuvant interferon alpha-2a treatment in resected primary cutaneous melanoma. Melanoma Res.(abstract). 7:1997.
35. Grob J. J., Dreno B., Delauney M. Randomised trial of interferon alpha 2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet. 351 (9120):1998 June 27;1905-1910.
36. Philip P. A., Flaherty L. Treatment of malignant melanoma with interleukin-2. Semin Oncol. 14 (Suppl 4):1997;32-38.
37. Rosenberg S. A., Yang J. C., Topalian S. L. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 271:1994;907-913.
38. Atkins M. B., Lotze M., Wiernik P. High dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma. Proc Am Soc Clin Oncol. 16:1997;494a.
39. Allen I. E., Kupelnick B., Kumashiro D. The combination of chemotherapy with IL-2 and IFN-A is more active than chemotherapy or immunotherapy alone in patients with metastatic melanoma: a meta-analysis of 7711 patients with metastatic melanoma. Proc Am Soc Clin Onc. 16:1997;494a(1781).
40. Sparano J. A., Fisher R. I., Sunderlaid M. Randomised phase III trial of treatment with high dose interleukin-2 either alone or in combination with interferon alpha 2a in patients with advanced melanoma. J Clin Oncol. 11:1993;1969-1977.
41. Kirkwood J. M., Ernstoff M. S., Giulamo A. Interferon alpha 2a and dacarbazine in melanoma. J Natl Cancer Inst. 82:1990;1062-1063.
42. Falkson, C. I. Falkson, G. Falkson, H. C. Improved results with the addition of interferon alpha 2b to dacarbazine in the treatment of metastastic melanoma, J Clin Oncol, 1991, 9, 1403, 1408.
43. Thomson D. B., Adena M., Mcleod G. R. Interferon alpha 2a does improve response when combined with dacarbazine in metastatic melanoma: Results of a multi-institutional Australian randomised trial. Melanoma Res. 3:1993;133-138.
44. Bajetta E., Di Leo A., Zampino M. G. Multi-centre trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha 2a in the treatment of advanced melanoma. J Clin Oncol. 12:1994;806-811.
45. Falkson C. I., Ibrahim J., Kirkwood J. M. A randomised phase III trial of dacarbazine (DTIC) versus DTIC + interferon alpha 2b versus DTIC + tamoxifen versus DTIC + IFN + TAM in metastatic melanoma: an ECOG trial. Proc Am Soc Clin Onc. 15:1996;435.
46. Hahka-Kemppinen M., Muhonen T., Virolainen M. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol. 132:1995;973-977.
47. Pyrhoren S., Hahka-Kemppien U., Muhonen T. A promising interferon plus 4 drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 10:1992;1919-1926.
48. Khayat D., Borel C., Tourani J. M. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 11:1993;2173-2180.
49. Keilholz U., Goey S. H., Punt C. J. A. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Co-operative Group. J Clin Oncol. 15:1997;1579-2588.
50. Richards J. M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 10:1992;1338-1343.
51. Richards J. M., Mehta, Schroeder L. Sequential chemoimmunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol. 11:1992;346.
52. Legha S. S., Ring S., Eton C. Durable complete responses in metastatic melanoma treated with biochemotherapy using cisplatin, vinblastine, dacarbazine (CVD) and interleukin-2 and interferon-α Proc Am Soc Clin Oncol. 14:1995;1305.
53. Legha S. Durable complete responses in metastatic melanoma treated with IL-2 in combination with IFN-A and chemotherapy. Semin Oncol. 14 (Suppl. 4):1997;39-43.
54. Legha S. S., Ring S., Bedikian A. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α Ann Oncol. 7:1996;827-835.
55. Legha S. S., Ring S., Eton C. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, IFN-A and IL-2 for patients with metastatic melanoma. J Clin Oncol. 5:1998;1752-1759.
56. Atzpodien J., Lopez-Hanninen E., Kirchner H. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous IL-2 and IFN-A after intravenous dacarbazine and carboplatin or dacarbazine cisplatin carmustine and tamoxifen. Eur J Cancer. 31A:1995;876-881.
57. Thompson J. A., Gold P. J., Fejer A. Outpatient chemoimmunotherapy in the treatment of metastatic melanoma. Semin Oncol. 14 (Suppl 4):1997;44-48.
58. Keilholz U., Conradt C., Legha S. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 9:1998;2921-2929.
59. Vaughan M. M., Moore J., Riches P. G. Phase I/II trial of biochemotherapy: ciplatin, DTIC, interleukin-2 (IL-2), and interferon-alpha (IFN-A) in combination with GM-CSF in malignant melanoma. Proc Am Soc Clin Oncol. 17:1998;507a.
60. Rosenberg S. A., Yang J. C., Schwartzentruber D. J. Prospective randomised trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa 2b. J Clin Oncol. 3:1999;968-975.
61. Keilholz U., Punt C. J., Gore M. E. Dacarbazine, cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: interim analysis of EORTC trial 18951. Proc Am Soc Clin Oncol. 18:1999;2043.
62. Morton D. L., Eilber F. R., Holmes E. C. Preliminary results of a randomised trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZ J Surg. 48 (1):1978 Feb;49-52.
63. Chan A. D., Morton D. L. Active immunotherapy with allogeneic tumour cell vaccines: Present status. Semin Oncol. 25 (6):1998;611-622.
64. Bystryn J. C., Oratz R., Shapiro R. L. Phase III double-blind, trial of a shed polyvalent, melanoma vaccine in stage III melnoma. Proc Am Soc Clin Oncol. 17:1998;434a.
65. Wallack M. K., Sivanandham M., Balch C. M. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III randomised, double-blind, multicenter vaccinia melanoma oncolysate trial. Jour Am Coll Surg. 187(1):1998;69-77.
66. Mitchell M. S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 15(6):1998;623-635.
67. Livingstone P. O., Wong G. Y., Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 5:1994;1036-1044.
68. Berd D., Maguire H. C., Bloome E. Regression of lung metastases after immunotherapy with autologous DNP modified melanoma vaccine. Proc Am Soc Clin Oncol. 17:1998;434a.
69. Berd D., Maguire H. C., Schuchter L. M. Autologous hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 15:1997;2359-2370.
70. Nestle F. O., Alijagic S., Gilliet M. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nature Med. 4:1998;328-332.
71. Rosenberg S. A., Yang J. C., Schwartzentruber D. J. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients of metastatic melanoma. Nature Med. 4:1998;321-327.